Investor Presentation Q1 2018

Investor Presentation First three months of 2018 Medications used for the treatment of type 2 diabetes Slide 40 Class HbA1c change Hypoglycae- Weight mia risk change Metformin 1.5 No Neutral Sulfonylurea 1.5 Yes Gain Commonly prescribed product classes for the treatment of type 2 diabetes Contraindication/ undesired effects Kidney, liver Essentially none CVD risk Dosing (pr. day) Minimal 2 OADs None 1 OAD TZDS 0.5-1.4 No Gain Varies 1 OAD DPP-IV inhibitors 0.6 -0.8 No Neutral TBD 1-2 OADs CHF, liver None SGLT-2 inhibitors 0.5 -0.9 No Loss GLP-1 1.0 - 2.0 No Loss Long-acting insulin 1.5-2.5 Yes Gain Fast-acting insulin 1.5-2.5 Yes Gain Genital infections, urinary tract infections GI side effects, MTC Hypoglycaemia Hypoglycaemia Note: TG and HDL: Beneficial effect on triglycerides and high-density lipoprotein cholesterol; CHF: Congestive heart failure; GI: Gastro intestinal; MTC: Medullary thyroid cancer; TZD: thiazolidinediones; OAD: Oral anti-diabetic; TBD: to be defined. Sources: Adapted from: Nathan DM, et al. Diabetes Care. 2006; 29:1963-1972; Nathan DM, et al. Diabetes Care. 2007;30:753-759; Nathan DM, et al. Diabetes Care. 2008;31:173-175. ADA. Diabetes Care. 2008;31:S12-S54. Wel Chol PI. 1/2008. Varies 1 OAD Varies Varies TG and HDL TG and HDL 1 injection 1-4 injections changing diabetes® novo nordisk

View entire presentation